Héloïse Cardinal
Dr. Héloïse Cardinal completed her undergraduate training at the Université de Sherbrooke. She completed her training in nephrology at the Université de Montréal and subsequently a master's and doctorate in epidemiology and biostatistics at McGill University. Dr. Cardinal is interested in biomarkers of vascular insult and their clinical utility in nephrology and transplantation. She has been actively involved in the characterization of anti-LG3 antibodies and their role in transplant patients. She is now focusing on characterizing the clinical utility of anti-LG3 in post-renal transplantation and on better understanding the permissive factors of the impact of anti-LG3 on blood vessels. She is also interested in mathematical models to help transplant physicians better inform patients about the pros and cons of accepting or rejecting offers of kidneys from expanded criteria donors. In addition to the Chair, her research program is or has been supported by the Fonds de recherche du Québec - santé, the Kidney Foundation of Canada, the Canadian Institutes of Health Research and the CHUM Research Centre.
This session will review the pediatric urinary CXCL10 monitoring implementation pilot RCT, with a view to obtaining input on how best to engage with patient participants and partners with the trial. We start by introducing the trial design and goals, which will be followed by review of patient engagement to date and a panel/audience discussion to solicit feedback. Topics for engagement include effective information for potential trial participants, ongoing updates during the trial and how to incorporate the patient voice in analysis of trial outcome and subsequent knowledge translation.
This session is sponsored by the Accelerating Clinical Trial Consortium.
This session is supported by the Canadian Institutes of Health Research (CIHR).
Speakers: Ke Fan Bei, Manuel Escoto, Sherrie Logan, Tom Blydt-Hansen, Héloïse Cardinal, Marie-Chantal Fortin
Log In
